Wiskott–Aldrich syndrome and X-linked thrombocytopenia: a review of the clinical and immunological spectrum with a case presentation highlighting glomerulonephritis - Scorecard - MDSpire
Advertisement
Wiskott–Aldrich syndrome and X-linked thrombocytopenia: a review of the clinical and immunological spectrum with a case presentation highlighting glomerulonephritis
Clinical Scorecard: Clinical and Immunological Insights into Wiskott–Aldrich Syndrome and X-Linked Thrombocytopenia: A Case Study Emphasizing Glomerulonephritis
At a Glance
Category
Detail
Condition
Wiskott–Aldrich Syndrome (WAS) and X-Linked Thrombocytopenia (XLT)
Key Mechanisms
Mutations in the WAS gene leading to immune dysregulation and thrombocytopenia.
Target Population
Primarily males with X-linked inheritance.
Care Setting
Pediatric nephrology and immunology.
Key Highlights
WAS is characterized by eczema, thrombocytopenia, and recurrent infections.
IgA nephropathy is a significant renal manifestation in WAS/XLT.
Dysregulated T- and B-cell function contributes to autoantibody formation.
Genetic testing confirmed a homozygous WAS variant in the presented case.
Registry data is essential for prognosis and therapeutic strategies.
Guideline-Based Recommendations
Diagnosis
Genetic testing for WAS gene mutations.
Clinical assessment of autoimmune manifestations.
Management
Multidisciplinary approach including nephrology and immunology.
Consider hematopoietic stem cell transplantation for severe cases.
Monitoring & Follow-up
Regular follow-up for renal function and autoimmune complications.
Monitoring of platelet counts and immune status.
Risks
Increased risk of infections and autoimmune disorders.
Potential for chronic kidney disease due to glomerulonephritis.
Patient & Prescribing Data
Children with WAS/XLT presenting with renal involvement.
Corticosteroids and immunoglobulins may be used for thrombocytopenia.
Clinical Best Practices
Early recognition of symptoms and genetic confirmation.
Age-specific management strategies for glomerular diseases.
